Values First Advisors Inc. Grows Stake in Exelixis, Inc. (NASDAQ:EXEL)

Values First Advisors Inc. raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 7.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,032 shares of the biotechnology company’s stock after buying an additional 1,207 shares during the quarter. Values First Advisors Inc.’s holdings in Exelixis were worth $409,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Contravisory Investment Management Inc. purchased a new position in Exelixis during the 4th quarter valued at approximately $26,000. Covestor Ltd grew its holdings in Exelixis by 245.6% during the 1st quarter. Covestor Ltd now owns 1,676 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,191 shares in the last quarter. Denali Advisors LLC grew its holdings in Exelixis by 7,995.2% during the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 1,679 shares in the last quarter. Fifth Third Bancorp grew its holdings in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 604 shares in the last quarter. Finally, Ronald Blue Trust Inc. grew its holdings in Exelixis by 87.2% during the 3rd quarter. Ronald Blue Trust Inc. now owns 2,552 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,189 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the subject of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Exelixis in a report on Friday, January 26th. Stifel Nicolaus lifted their target price on Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Friday, February 2nd. TheStreet raised Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. Barclays lifted their target price on Exelixis from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Tuesday, January 30th. Finally, BTIG Research started coverage on Exelixis in a report on Tuesday, December 19th. They issued a “buy” rating and a $27.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.29.

Insider Buying and Selling at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 47,020 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares in the company, valued at approximately $8,255,375.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Alan M. Garber sold 19,205 shares of the business’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $24.01, for a total value of $461,112.05. Following the completion of the transaction, the director now owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 47,020 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total value of $1,008,579.00. Following the completion of the transaction, the executive vice president now directly owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Company insiders own 2.90% of the company’s stock.

Exelixis Price Performance

Exelixis stock traded down $0.13 during trading hours on Thursday, hitting $23.73. 2,953,471 shares of the stock traded hands, compared to its average volume of 2,365,561. The firm’s 50 day moving average price is $21.99 and its 200-day moving average price is $21.97. The stock has a market capitalization of $7.19 billion, a price-to-earnings ratio of 37.28, a P/E/G ratio of 0.62 and a beta of 0.53. Exelixis, Inc. has a 1 year low of $18.08 and a 1 year high of $24.34.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. The business had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. Research analysts forecast that Exelixis, Inc. will post 1.22 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.